The Future of Alzheimer's Treatment: Promising Drugs and Blockbuster Stocks.

Eli Lilly's experimental Alzheimer's treatment, donanemab, is expected to gain approval and generate $465 million in sales in 2024, with projected sales of $1.4 billion and $3.2 billion in 2025 and 2030, respectively. The company is also working on a subcutaneous shot and an oral treatment for Alzheimer's disease. Analysts expect Medicare officials to sign off on reimbursement for donanemab and other anti-amyloid beta Alzheimer's treatments. Biogen and Eisai's Leqembi, which gained FDA accelerated approval in January, is a potential rival to donanemab.